Summary:
All subjects in the study will have had loss of response or intolerance to conventional medication used to treat Crohn’s disease.
Study Periods:
Screening (Approximately 4 Weeks)
Period 1 (Weeks 0 to 12): A 12-week dosing period, where the medication would be administer to the subjects.
Period 2 (Weeks 12 to 52): In Period 2, all subjects will continue dosing.
Period 3 (Weeks 52 to 104): All subjects having clinical benefit will continue on study in Period 3
Follow-Up: At Week 104, subjects will stop treatment and be followed for safety for an additional 16 weeks.
Qualified Participants Must:
• Diagnosed with Crohn's Disease
Qualified Participants May Receive:
Monetary compensation upto $2,300 for time and travel